23928 BI-WUXI@EC2412A.C
- 0.062
- -0.037-37.37%
Pharmaceutical Biotech (2269.HK): Recovery in global biomedical financing drives valuation and performance restoration
[Brokerage Focus] morgan stanley slightly cuts wuxi bio (02269) target price by 1.25%, stating that it will continue to maintain a leading position in the china market.
Pharmaceutical Biotech (2269.HK): The adjusted profit attributable to the company's shareholders fell 20.7% year-on-year in the first half of '24
[Brokerage Focus] China Merchants maintains a "shareholding" rating for Wuxi Bio (02269), pointing to the expansion of the animal health biopharmaceutical field that is expected to bring incremental performance.
Pharmaceutical Biotech (02269.HK): Launching a one-stop solution for veterinary medicine, opening up new markets and contributing to new volume
Pharmaceutical Biotech (02269.HK): Ongoing orders remain high and the “follow and win molecules” strategy continues to advance
Pharmaceutical Biotech (2269.HK): New projects continue to grow and maintain the 24-year guideline
Pharmaceutical Biotech (02269.HK): Steady overall growth in non-COVID-19 revenue continues to improve global production capacity layout
WUXI BIOLOGICS(2269.HK):1H24 MARGINS DECLINED;US REVENUE PROPORTION EXPANDED TO 58%
Pharmaceutical Biotech (2269.HK): Newly signed projects continue to increase, and the three major RDM sectors will accelerate improvement in the second half of the year
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$19.30 From HK$23.25, Keeps at Buy
Pharmaceutical Biotech (2269.HK): 1H24's performance is in line with expectations, but short-term uncertainty remains, maintaining a neutral rating
Pharmaceutical Biotech (02269.HK): XDC achieved rapid growth and remained unchanged in the 2024 full-year guideline
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$23.25 From HK$53.65, Keeps at Buy
Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target Is HK$14
Big Bank Rating | Jefferies: The upward potential of Pharmaceutical Biotech is greater than the downward potential rating “buy”
Big Bank Ratings | Jefferies: From the perspective of market accounts, Yao Ming Biotech is currently at an inflection point rating “buying”
Big Bank Ratings | Jefferies: From the perspective of market accounts, Yao Ming Biotech is currently at an inflection point rating “buying”
Research and Development | China Merchants Securities: Drastic reduction in the target price of Pharmaceutical Biotech to HK$13, downgrading the rating to “neutral”
Pharmaceutical Biotech (02269.HK): Opening a New Chapter in Global Operations, Multiple Engines Drive Growth